On July 4, 2024, Shilpa Medicare Limited (SML) announced in a stock exchange filing that its CDMO (contract development and manufacturing organisation) customer, Unicycive Therapeutics, Inc., has reported positive results from the pivotal clinical trial of Oxylanthanum Carbonate (OLC), a new chemical entity (NCE) molecule with potential treatment for hyperphosphatemia in chronic kidney disease patients. …


